nach oben

World Journal of Urology

Erschienen in:

10.02.2018 | Invited Review

Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma

verfasst von: M. Hegemann, N. Kroeger, A. Stenzl, J. Bedke

Erschienen in: World Journal of Urology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Paraneoplastic syndromes (PNS) in renal cell carcinoma (RCC) are important to be recognized by the treating physician, because they may lead to diagnosis of underlying malignant disease. On the other hand, PNS may dominate the clinical picture and can hide the true disorder like a chameleon. When realized, a PNS can be used as a ‘neoplastic tumour marker’, especially in case of recurrence. Their occurrence can even be linked to prognosis of disease.

Methods

A PubMed search combining the MeSH terms renal cell carcinoma and paraneoplastic syndrome was executed in April 2015. All hits concerning these MeSH terms have been taken into account when writing this review.

Results

There is a big gap between reporting and incidence of paraneoplastic syndromes in renal cell carcinoma. Most of the articles in Medline are case reports and reviews of research done in the 1950s–1990s. One problem is that a clear definition of a paraneoplastic syndrome is still lacking. The most important PNS in RCC are hypercalcemia. It is important that PNS are not only arising in advanced stages of renal cell carcinoma; in contrast, a PNS can often be the first symptom of RCC.

Conclusion

Paraneoplastic syndromes are often unrecognized but are important biomarkers in RCC. Further research into the underlying pathomechanisms of PNS may improve our understanding of the RCC tumour biology and is urgently needed.

Forman D, Bray F, Brewster DH (2017) Cancer incidence in five continents Vol. X http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/CI5volX_Full.pdf. Accessed 11 May 2017

Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M et al (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58:588–595CrossRefPubMed

Lee CT, Katz J, Fearn PA, Russo P (2002) Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol Semin Orig Investig 7:135–140 (Elsevier) CrossRef

Ding G-X, Song N-H, Feng C-C, Xia G-W, Jiang H-W, Hua L-X et al (2012) Is there an association between advanced stage of renal cell carcinoma and paraneoplastic syndrome? Med Princ Pract 21:370–374CrossRefPubMed

Palapattu GS, Kristo B, Rajfer J (2002) Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol 4:163–170PubMedPubMedCentral

Kim HL, Belldegrun AS, Freitas DG, Bui MHT, Han K-R, Dorey FJ et al (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170:1742–1746CrossRefPubMed

Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A et al (2009) Paraneoplastic syndromes in patients with urological malignancies. Urol Int 83:1–11CrossRefPubMed

Mohammed Ilyas M, Turner G, Cranston D (2008) Human chorionic gonadotropin-secreting clear cell renal cell carcinoma with paraneoplastic gynaecomastia. Scand J Urol Nephrol 42:555–557CrossRefPubMed

Gold PJ, Fefer A, Thompson JA (1996) Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 14:216–222PubMed

10.

Ding G, Feng C, Song N, Fang Z, Xia G, Jiang H et al (2013) Paraneoplastic symptoms: cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma. Urol Oncol Semin Orig Investig 31:1820–1825CrossRef

11.

Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG (1978) Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 119:468–471CrossRefPubMed

12.

Goldberg MF, Tashjian AH, Order SE, Dammin GJ (1964) Renal adenocarcinoma containing a parathyroid hormone-like substance and associated with marked hypercalcemia. Am J Med 36:805–814CrossRefPubMed

13.

Buckle RM, McMillan M, Mallinson C (1970) Ectopic secretion of parathyroid hormone by a renal adenocarcinoma in a patient with hypercalcaemia. Br Med J 4:724–726CrossRefPubMedPubMedCentral

14.

Weissglas M, Schamhart D, Löwik C, Papapoulos S, Vos P, Kurth KH (1995) Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 153:854–857CrossRefPubMed

15.

Muggia FM (1990) Overview of cancer-related hypercalcemia: epidemiology and etiology. Semin Oncol 17:3–9PubMed

16.

Mundy GR (1990) Pathophysiology of cancer-associated hypercalcemia. Semin Oncol 17:10–15PubMed

17.

Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinoma. Urology 33:167–170CrossRefPubMed

18.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540CrossRefPubMed

19.

Adhikaree J, Newby Y, Sundar S (2014) Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep 2014:bcr2013202861CrossRefPubMedPubMedCentral

20.

Sufrin G, Mirand EA, Moore RH, Chu TM, Murphy GP (1977) Hormones in renal cancer. J Urol 117:433–438CrossRefPubMed

21.

Moein MR, Dehgahni VO (2000) Hypertension: a rare presentation of renal cell carcinoma. J Urol 164:2019CrossRefPubMed

22.

Dahl T, Eide I, Fryjordet A (1981) Hypernephroma and hypertension. Two case reports. Acta Med Scand 209:121–124CrossRefPubMed

23.

Wiesener MS, Seyfarth M, Warnecke C, Jürgensen JS, Rosenberger C, Morgan NV et al (2002) Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 99:3562–3565CrossRefPubMed

24.

Sherwood JB, Burns ER, Shouval D (1987) Stimulation by cAMP of erythropoietin secretion by an established human renal carcinoma cell line. Blood 69:1053–1057PubMed

25.

Cho EJ, Lee HJ, Park KU, Kim U-Y, Lee HJ, Bang SM (2014) Immune thrombocytopenic purpura in a patient with renal cell carcinoma. Korean J Intern Med 29:671CrossRefPubMedPubMedCentral

26.

Wang Y-C, Yang S, Tzen C-Y, Lin C-C, Lin J (2006) Renal cell carcinoma producing granulocyte colony-stimulating factor. J Formos Med Assoc Taiwan Yi Zhi 105:414–417CrossRefPubMed

27.

Todenhöfer T, Wirths S, von Weyhern CH, Heckl S, Horger M, Hennenlotter J et al (2012) Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma. BMC Urol 12:7CrossRefPubMedPubMedCentral

28.

Kirkali Z, Esen AA, Kirkali G, Güner G (1995) Ferritin: a tumor marker expressed by renal cell carcinoma. Eur Urol 28:131–134CrossRefPubMed

29.

Loughlin KR, Gittes RF, Partridge D, Stelos P (1987) The relationship of lactoferrin to the anemia of renal cell carcinoma. Cancer 59:566–571CrossRefPubMed

30.

Pavelić K, Popović M (1981) Insulin and glucagon secretion by renal adenocarcinoma. Cancer 48:98–100CrossRefPubMed

31.

Watanobe H, Yoshioka M, Takebe K (1988) Ectopic ACTH syndrome due to Grawitz tumor. Horm Metab Res Horm Stoffwechselforschung Horm Métabolisme 20:453–456CrossRef

32.

Riggs BL, Sprague RG (1961) Association of cushing’s syndrome and neoplastic disease: observations in 232 cases of cushing’s syndrome and review of the literature. Arch Intern Med 108:841–849CrossRefPubMed

33.

Turkington RW (1971) Ectopic Production of Prolactin. N Engl J Med 285:1455–1458CrossRefPubMed

34.

Resnick ME, Unterberger H, McLoughlin PT (1966) Renal carcinoid producing the carcinoid syndrome. Med Times 94:895–896PubMed

35.

McCaffrey JA, Reuter V, Herr HW, Macapinlac HA, Russo P, Motzer RJ (2000) Carcinoid tumor of the kidney: the use of somatostatin receptor scintigraphy in diagnosis and management. Urol Oncol Semin Orig Investig 5:108–111 (Elsevier) CrossRef

36.

Kwatra A, McDonald RE, Corriere JRJN (1998) Erythema gyratum repens in association with renal cell carcinoma. J Urol 159:2077CrossRefPubMed

37.

Levy O, Tishler M (2009) Acquired ichthyosis as the primary manifestation of renal cell carcinoma. Isr Med Assoc J 11:121PubMed

38.

Yan K, Liu C, Xu Z, Liu Z, Wang K, Jiang Y et al (2013) Renal cell carcinoma presenting as exfoliative dermatitis (erythroderma)—a case report. Clin Nephrol 80:63–66CrossRefPubMed

39.

Ducarme G, Rey D, Bryckaert P-E, Reguiai Z, Bernard P, Staerman F (2003) Paraneoplastic urticarial vasculitis and renal carcinoma]. Prog En Urol J Assoc Fr Urol Société Fr Urol 13:495–497

40.

Rajpara A, Liolios A, Fraga G, Blackmon J (2014) Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer. Dermatol Online J 20(6)

41.

Yilmaz S, Karakas A, Cinar M, Coskun O, Simsek I, Erdem H et al (2013) Adult onset still’s disease as a paraneoplastic syndrome. Bull Hosp Joint Dis 71:156–160

42.

Moscardi JL, Macedo NA, Espasandin JA, Piñeyro MI (1993) Malignant acanthosis nigricans associated with a renal tumor. Int J Dermatol 32:893–894CrossRefPubMed

43.

Saravanan K, Baer ST, Meredith A, Dyson A, von der Werth J (2006) Benign mucous membrane pemphigoid of the upper aero-digestive tract: rare paraneoplastic syndrome presentation in renal cell carcinoma. J Laryngol Otol 120:237–239CrossRefPubMed

44.

Vanatta PR, Silva FG, Taylor WE, Costa JC (1983) Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature. Hum Pathol 14:195–201CrossRefPubMed

45.

Schaefer O, Lohrmann C, Harder J, Veelken H, Langer M (2004) Treatment of renal cell carcinoma-associated dermatomyositis with renal arterial embolization and percutaneous radiofrequency heat ablation. J Vasc Interv Radiol JVIR 15:97–99CrossRefPubMed

46.

Harrison JW, Cherukuri R, Buchan D (2015) Renal cell carcinoma presenting with paraneoplastic hallucinations and cognitive decline from limbic encephalitis. J Gen Intern Med 30:1037–1040CrossRefPubMedPubMedCentral

47.

Johnson V, Friedman N, Haller NA, Hagel C (2008) Immune mediated neurologic dysfunction as a paraneoplastic syndrome in renal cell carcinoma. J Neurooncol 90:279–281CrossRefPubMed

48.

Thomas NE, Passamonte PM, Sunderrajan EV, Andelin JB, Ansbacher LE (1984) Bilateral diaphragmatic paralysis as a possible paraneoplastic syndrome from renal cell carcinoma. Am Rev Respir Dis 129:507–509PubMed

49.

McHugh JC, Murray B, Renganathan R, Connolly S, Lynch T (2007) GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 22:1343–1346CrossRefPubMed

50.

Turk HM, Ozet A, Kuzhan O, Komurcu F, Arpaci F, Ozturk B et al (2009) Paraneoplastic motor neuron disease resembling amyotrophic lateral sclerosis in a patient with renal cell carcinoma. Med Princ Pract 18:73–75CrossRefPubMed

51.

Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554CrossRefPubMed

52.

Stauffer JM, Granville GE, Law SW (1961) Recurrent hypoglycemia and retroperitoneal fibrosarcoma. N Engl J Med 265:979–982CrossRefPubMed

53.

Aoyagi T, Mori I, Ueyama Y, Tamaoki N (1989) Sinusoidal dilatation of the liver as a paraneoplastic manifestation of renal cell carcinoma. Hum Pathol 20:1193–1197CrossRefPubMed

54.

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S et al (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer J Int Cancer 72:424–430CrossRef

55.

Giannakos G, Papanicolaou X, Trafalis D, Michaelidis I, Margaritis G, Christofilakis C (2005) Stauffer’s syndrome variant associated with renal cell carcinoma. Int J Urol 12:757–759CrossRefPubMed

56.

Kurban M, Uthman I, Kibbi A-G, Ghosn S (2008) Acquired perforating dermatosis heralding metastatic renal cell carcinoma to the liver. Int J Dermatol 47:1038–1040CrossRefPubMed

57.

Ibrahim TM, Iheonunekwu N (2009) Secondary amyloidosis of the conjunctiva and mucosa of upper respiratory tract associated with renal cell carcinoma: case report and review of literature. Niger J Med J Natl Assoc Resid Dr Niger 18:172–174

58.

Triginer C, Fernández R, Sánchez JM, Net A (1989) Dermatomyositis and hypernephroma. Rev Clínica Esp 184:110

59.

Nevins E, Zayat AS, Browning AJ, Biyani CS, Jarrett S (2013) Renal cell carcinoma-associated adult dermatomyositis treated laparoscopic nephrectomy. Urol Ann 5:299–301CrossRefPubMedPubMedCentral

60.

Sarma PK, Aggarwal A, Misra R, Chauhan A, Agarwal V (2011) Renal cell carcinoma and systemic onset juvenile idiopathic arthritis. Indian J Med Sci 65:107–111CrossRefPubMed

61.

Lee CM, Sim A, Kurugulasigamoney G, Ng LG (2015) Heart failure as the first manifestation of renal cell carcinoma. Korean J Urol 56:82CrossRefPubMedPubMedCentral

Titel: Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma
verfasst von: M. Hegemann
N. Kroeger
A. Stenzl
J. Bedke
Publikationsdatum: 10.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2215-9

Neu im Fachgebiet Urologie

10.04.2024 | PSA-Screening | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma

Abstract

Introduction

Methods

Results

Conclusion

Neu im Fachgebiet Urologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

TURP hat Vorteile im Vergleich mit der Embolisation

Langes Sitzen in der Freizeit korreliert mit erektiler Dysfunktion

Update Urologie

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial

Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study

Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF–III renal cysts: a multicenter study

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial

Assessment of readability, quality and popularity of online information on ureteral stents

Neu im Fachgebiet Urologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

TURP hat Vorteile im Vergleich mit der Embolisation

Langes Sitzen in der Freizeit korreliert mit erektiler Dysfunktion

Update Urologie